Action Hancock Jaffe Laboratories - HJLI

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

10,38

Prix Achat

10,00

Prix Vente

10,70

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Cap du marché

98,319M

Clôture Veille

10,38

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

Actions en circulation

9 472 000

Rendement du Dividende

Ratio Cours sur Bénéfices

-4,18

Bénéfice par action (BPA)

-2,48

Chiffre d'affairess

Bénéfice net

-23,52M

Secteur

Surgical,med Instr,apparatus

Industrie

Surgical,med Instr,apparatus

Site Web

www.envveno.com

Siège social

Wilmington, Delaware, USA

Fondé

Hancock Jaffe Successfully Starts First-in-Human VenoValve Study

IRVINE, Calif., Feb. 19, 2019 (GLOBE NEWSWIRE) -- Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a...

Hancock Jaffe Announces Objectives for Upcoming CoreoGraft Study

IRVINE, Calif., Jan. 28, 2019 (GLOBE NEWSWIRE) -- Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a...

Dr. Marc H. Glickman to Present at 6th Israeli Vascular Access Conference

IRVINE, Calif., Jan. 15, 2019 (GLOBE NEWSWIRE) -- Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a...

Hancock Jaffe Announces End Points for First-in-Human VenoValve Study

IRVINE, Calif., Jan. 09, 2019 (GLOBE NEWSWIRE) -- Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a...

Hancock Jaffe Receives Approval for First-in-Human VenoValve Study

IRVINE, Calif., Dec. 17, 2018 (GLOBE NEWSWIRE) -- Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a...

Hancock Jaffe Announces January CoreoGraft Study at the Texas Heart Institute

IRVINE, Calif., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a...

Hancock Jaffe Updates Status of Application to INVIMA for First-In-Human VenoValve Trial in Colombia

IRVINE, Calif., Nov. 20, 2018 (GLOBE NEWSWIRE) -- Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a...

Hancock Jaffe Appoints Chris Sarner as Vice President of Regulatory Affairs and Quality Assurance

IRVINE, Calif., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a...

Hancock Jaffe Enters into Sponsored Research Agreement for CoreoGraft with World-Renowned Texas Heart Institute

IRVINE, Calif., Oct. 09, 2018 (GLOBE NEWSWIRE) -- Hancock Jaffe Laboratories, Inc. (Nasdaq: HJLI, HJLIW), a...

Hancock Jaffe Appoints Three New Independent Directors

Accomplished medical device professionals and nationally recognized fund manager and analystbring key...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

HJLI - Frequently Asked Questions (FAQ)

What is the current Hancock Jaffe Laboratories share price?

The current share price of Hancock Jaffe Laboratories is US$ 10,38

How many Hancock Jaffe Laboratories shares are in issue?

Hancock Jaffe Laboratories has 9 472 000 shares in issue

What is the market cap of Hancock Jaffe Laboratories?

The market capitalisation of Hancock Jaffe Laboratories is USD 98,32M

What is the 1 year trading range for Hancock Jaffe Laboratories share price?

Hancock Jaffe Laboratories has traded in the range of US$ 0,00 to US$ 0,00 during the past year

What is the PE ratio of Hancock Jaffe Laboratories?

The price to earnings ratio of Hancock Jaffe Laboratories is -4,18

What is the reporting currency for Hancock Jaffe Laboratories?

Hancock Jaffe Laboratories reports financial results in USD

What is the latest annual profit for Hancock Jaffe Laboratories?

The latest annual profit of Hancock Jaffe Laboratories is USD -23,52M

What is the registered address of Hancock Jaffe Laboratories?

The registered address for Hancock Jaffe Laboratories is 251 LITTLE FALLS DRIVE, NEW CASTLE, WILMINGTON, DELAWARE, 19808

What is the Hancock Jaffe Laboratories website address?

The website address for Hancock Jaffe Laboratories is www.envveno.com

Which industry sector does Hancock Jaffe Laboratories operate in?

Hancock Jaffe Laboratories operates in the SURGICAL,MED INSTR,APPARATUS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
VRPXVirpax Pharmaceuticals Inc	US$ 0,515 (78,26%)	22,97M
CNTMConnectM Technology Solutions Inc	US$ 1,15 (22,80%)	3,44M
AMODAlpha Modus Holdings Inc	US$ 4,13 (14,09%)	989,74k
ABNBAirbnb Inc	US$ 159,02 (12,75%)	3,38M
ROKURoku Inc	US$ 96,6901 (11,39%)	3,08M
BLACBellevue Life Sciences Acquisition Corporation	US$ 4,75 (-32,62%)	8,48k
HCTIHealthcare Triangle Inc	US$ 0,4718 (-19,24%)	1,3M
BSLKBolt Projects Holdings Inc	US$ 0,9944 (-19,15%)	7,17M
AENTAlliance Entertainment Holding Corporation	US$ 4,29 (-17,18%)	6,23k
APTOAptose Biosciences Inc	US$ 0,17495 (-16,17%)	1,03M
VRPXVirpax Pharmaceuticals Inc	US$ 0,515 (78,26%)	22,97M
MGOLMGO Global Inc	US$ 0,8426 (-0,28%)	9,73M
BSLKBolt Projects Holdings Inc	US$ 0,9944 (-19,15%)	7,17M
MBRXMoleculin Biotech Inc	US$ 1,1399 (-10,24%)	6,1M
ADTXAditxt Inc	US$ 0,0717 (-4,27%)	5,52M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Hancock Jaffe Laboratories Inc (HJLI)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Hancock Jaffe Laboratories Inc

HJLI Dernières nouvelles

Hancock Jaffe Successfully Starts First-in-Human VenoValve Study

Hancock Jaffe Announces Objectives for Upcoming CoreoGraft Study

Dr. Marc H. Glickman to Present at 6th Israeli Vascular Access Conference

Hancock Jaffe Announces End Points for First-in-Human VenoValve Study

Hancock Jaffe Receives Approval for First-in-Human VenoValve Study

Hancock Jaffe Announces January CoreoGraft Study at the Texas Heart Institute

Hancock Jaffe Updates Status of Application to INVIMA for First-In-Human VenoValve Trial in Colombia

Hancock Jaffe Appoints Chris Sarner as Vice President of Regulatory Affairs and Quality Assurance

Hancock Jaffe Enters into Sponsored Research Agreement for CoreoGraft with World-Renowned Texas Heart Institute

Hancock Jaffe Appoints Three New Independent Directors

HJLI - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Hancock Jaffe Laboratories Inc (HJLI) Cours

Hancock Jaffe Laboratories Inc (HJLI)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

À propos de Hancock Jaffe Laboratories Inc

HJLI Dernières nouvelles

Hancock Jaffe Successfully Starts First-in-Human VenoValve Study

Hancock Jaffe Announces Objectives for Upcoming CoreoGraft Study

Dr. Marc H. Glickman to Present at 6th Israeli Vascular Access Conference

Hancock Jaffe Announces End Points for First-in-Human VenoValve Study

Hancock Jaffe Receives Approval for First-in-Human VenoValve Study

Hancock Jaffe Announces January CoreoGraft Study at the Texas Heart Institute

Hancock Jaffe Updates Status of Application to INVIMA for First-In-Human VenoValve Trial in Colombia

Hancock Jaffe Appoints Chris Sarner as Vice President of Regulatory Affairs and Quality Assurance

Hancock Jaffe Enters into Sponsored Research Agreement for CoreoGraft with World-Renowned Texas Heart Institute

Hancock Jaffe Appoints Three New Independent Directors

HJLI - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	CS
4	0	0	0	0	0	0	0	CS
12	0	0	0	0	0	0	0	CS
26	0	0	0	0	0	0	0	CS
52	0	0	0	0	0	0	0	CS
156	0	0	0	0	0	0	0	CS
260	0	0	0	0	0	0	0	CS